OKLAHOMA Health Care Authority | Serving Oklahomans through SoonerCare

August 28, 2023

RE: Prior Authorization of Nyvepria™ - Effective September 15, 2023

Effective September 15, 2023, the Oklahoma Health Care Authority (OHCA) will require a prior authorization (PA) for Nyvepria™ (pegfilgrastim-apgf). **No PA is required for Fulphila® (pegfilgrastim-jmdb), Fylnetra™ (pegfilgrastim-pbbk), Ziextenzo® (pegfilgrastim-bmez), Granix® (tbo-filgrastim), Neupogen® (filgrastim), or Zarxio® (filgrastim-sndz).** Please note, Neulasta® (pegfilgrastim), Stimufend® (pegfilgrastim-fpgk), Udenyca® (pegfilgrastim-cbqv), Nivestym® (filgrastim-aafi), and Releuko™ (filgrastim-ayow) continue to require a PA.

Neulasta® (Pegfilgrastim), Nyvepria™ (Pegfilgrastim-apgf), Stimufend® (Pegfilgrastim-fpgk), and Udenyca® (Pegfilgrastim-cbqv) Approval Criteria:

1. An FDA approved diagnosis; and
2. A patient-specific, clinically significant reason why the member cannot use Fulphila® (pegfilgrastim-jmdb), Fylnetra™ (pegfilgrastim-pbbk), Granix® (tbo-filgrastim), Neupogen® (filgrastim), Zarxio® (filgrastim-sndz), or Ziextenzo® (pegfilgrastim-bmez) must be provided. Biosimilars and/or reference products are preferred based on the lowest net cost product(s) and may be moved to either preferred or non-preferred if the net cost changes in comparison to the reference product and/or other available biosimilar products.

The specific PA requirements for the granulocyte colony-stimulating factor (G-CSF) products are available on the OHCA website at www.oklahoma.gov/ohca/pa in the “Biologics” therapeutic category. A specific PA form is required for the non-preferred G-CSF products (PHARM-208), which is located on the OHCA website at www.oklahoma.gov/ohca/rxforms.

Thank you for the services you provide to Oklahomans insured by SoonerCare!